pirfenidone has been researched along with sirolimus in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Latham, CW; Margolin, SB; Visner, GA; Zander, DS; Zhou, H | 1 |
| Bizargity, P; Hancock, WW; Liu, F; Liu, H; Liu, K; Visner, GA; Wang, L; Yang, J | 1 |
| Darwiche, K; Freitag, L; Mairinger, FD; Walter, RF; Werner, R; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Belloli, EA; Flaherty, KR; Martinez, FJ | 1 |
| Dorca, J; Escobar, I; Llatjós, R; Luburich-Hernaiz, P; Machahua-Huamani, C; Molina-Molina, M; Montes-Worboys, A; Sala-Llinas, E; Vicens-Zygmunt, V | 1 |
| Hu, H; Li, F; Liu, F; Ma, W; Pan, Q; Ran, C; Wang, J; Yang, Q | 1 |
1 review(s) available for pirfenidone and sirolimus
| Article | Year |
|---|---|
Update in Interstitial Lung Disease 2014.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Doxycycline; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Lymphangioleiomyomatosis; Pyridones; Sarcoidosis, Pulmonary; Sirolimus; Smoking; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha | 2015 |
6 other study(ies) available for pirfenidone and sirolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclosporine; Disease Models, Animal; Female; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; Trachea; Transforming Growth Factor beta | 2005 |
Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.
Topics: Adoptive Transfer; Animals; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Chemokines; Cytokines; Drug Therapy, Combination; Graft Rejection; Heart Transplantation; Histocompatibility; Immunosuppressive Agents; Isoantigens; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Time Factors | 2009 |
Cell viability of fibroblasts to pifenidone and sirolimus: a future concept for drug eluting stents.
Topics: Apoptosis; Caspase 3; Caspase 7; Cell Line; Cell Survival; Drug-Eluting Stents; Fibroblasts; Humans; Immunosuppressive Agents; L-Lactate Dehydrogenase; Pyridones; Sirolimus | 2014 |
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
Topics: A549 Cells; Alveolar Epithelial Cells; Biomarkers; Cell Movement; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Idiopathic Pulmonary Fibrosis; Myofibroblasts; Pyridones; Sirolimus; Transforming Growth Factor beta1 | 2018 |
A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Biliary Tract Diseases; Constriction, Pathologic; Disease Models, Animal; Drug Evaluation, Preclinical; Pyridones; Rabbits; Secondary Prevention; Sirolimus; Vasodilator Agents | 2018 |